Literature DB >> 29519866

Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study.

Guillaume Cartron1,2, Rémi Letestu3, Caroline Dartigeas4, Mira Tout5, Béatrice Mahé6, Anne-Laure Gagez7, Emmanuelle Ferrant8, Boris Guiu9, Bruno Villemagne10, Phan Letuan11, Thérèse Aurran12, Frédérique Orsini-Piocelle13, Anne Banos14, Pierre Feugier15, Véronique Leblond16, Sophie de Guibert17, Olivier Tournilhac18, Jehan Dupuis19, Alain Delmer20, Valérie Rouillé7, David Ternant5,21, Stéphane Leprêtre22.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29519866      PMCID： PMC6068027          DOI： 10.3324/haematol.2017.182352

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Adrenal gland volume measurement in septic shock and control patients: a pilot study.

Authors:  Stephanie Nougaret; B Jung; S Aufort; G Chanques; S Jaber; B Gallix
Journal:  Eur Radiol       Date:  2010-06-04       Impact factor: 5.315

3.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Authors:  M Hallek; K Fischer; G Fingerle-Rowson; A M Fink; R Busch; J Mayer; M Hensel; G Hopfinger; G Hess; U von Grünhagen; M Bergmann; J Catalano; P L Zinzani; F Caligaris-Cappio; J F Seymour; A Berrebi; U Jäger; B Cazin; M Trneny; A Westermann; C M Wendtner; B F Eichhorst; P Staib; A Bühler; D Winkler; T Zenz; S Böttcher; M Ritgen; M Mendila; M Kneba; H Döhner; S Stilgenbauer
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

4.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

Authors:  J C Byrd; T Murphy; R S Howard; M S Lucas; A Goodrich; K Park; M Pearson; J K Waselenko; G Ling; M R Grever; A J Grillo-Lopez; J Rosenberg; L Kunkel; I W Flinn
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

5.  Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia.

Authors:  Jing Li; Jianguo Zhi; Michael Wenger; Nancy Valente; Anna Dmoszynska; Tadeusz Robak; Ranvir Mangat; Amita Joshi; Jennifer Visich
Journal:  J Clin Pharmacol       Date:  2012-01-10       Impact factor: 3.126

6.  Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.

Authors:  Sebastian Böttcher; Matthias Ritgen; Kirsten Fischer; Stephan Stilgenbauer; Raymonde M Busch; Günter Fingerle-Rowson; Anna Maria Fink; Andreas Bühler; Thorsten Zenz; Michael Karl Wenger; Myriam Mendila; Clemens-Martin Wendtner; Barbara F Eichhorst; Hartmut Döhner; Michael J Hallek; Michael Kneba
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

7.  Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.

Authors:  Mira Tout; Anne-Laure Gagez; Stéphane Leprêtre; Valérie Gouilleux-Gruart; Nicolas Azzopardi; Alain Delmer; Mélanie Mercier; Loïc Ysebaert; Kamel Laribi; Hugo Gonzalez; Gilles Paintaud; Guillaume Cartron; David Ternant
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

8.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

9.  Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.

Authors:  David Daydé; David Ternant; Marc Ohresser; Stéphanie Lerondel; Sabrina Pesnel; Hervé Watier; Alain Le Pape; Pierre Bardos; Gilles Paintaud; Guillaume Cartron
Journal:  Blood       Date:  2008-11-24       Impact factor: 22.113

10.  Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

Authors:  Stephen A Beers; Ruth R French; H T Claude Chan; Sean H Lim; Timothy C Jarrett; Regina Mora Vidal; Sahan S Wijayaweera; Sandra V Dixon; Hyungjin Kim; Kerry L Cox; Jonathan P Kerr; David A Johnston; Peter W M Johnson; J Sjef Verbeek; Martin J Glennie; Mark S Cragg
Journal:  Blood       Date:  2010-03-11       Impact factor: 22.113
View more
  1 in total

1.  Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.

Authors:  Candice Jamois; Ekaterina Gibiansky; Leonid Gibiansky; Vincent Buchheit; Denis Sahin; Guillaume Cartron; Robert Marcus; Wolfgang Hiddemann; John F Seymour; Jonathan C Strefford; Chantal E Hargreaves; Georgina Meneses-Lorente; Nicolas Frey; Günter Fingerle-Rowson
Journal:  Br J Clin Pharmacol       Date:  2019-05-17       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.